Måling av kalprotektin i feces

Tidsskrift for den Norske Laegeforening

Volumn 129, Issue 8, 2009, Pages 743-745

  Jahnsen, Jørgen ^a   Røseth, Arne G ^b   Aadland, Erling ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b Medisinsk Avdeling   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CALGRANULIN;

ADULT; CHEMISTRY; DIFFERENTIAL DIAGNOSIS; ENTERITIS; FECES; HUMAN; IMMUNOLOGY; IRRITABLE COLON; PREDICTION AND FORECASTING; REVIEW; SENSITIVITY AND SPECIFICITY;

ADULT; BIOLOGICAL MARKERS; DIAGNOSIS, DIFFERENTIAL; FECES; HUMANS; INFLAMMATORY BOWEL DISEASES; IRRITABLE BOWEL SYNDROME; LEUKOCYTE L1 ANTIGEN COMPLEX; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY;

EID: 64849109629     PISSN: 00292001     EISSN: 08077096     Source Type: Journal    
DOI: 10.4045/tidsskr.08.0010     Document Type: Article

References (33)

1. Fliedner SH, Cronkite EP, Robertson JS. Granulopoesis, senescence and random loss of neutrophilic granulocytes in human beings. Blood 1964; 24: 404-14.
2. Fagerhol MK, Dale I, Andersson T. Release and quantification of a leucocyte derived protein (L1). Scand J Haematol 1980; 24: 393-8.
3. Steinbakk M, Naess-Andresen CF, Lingaas E. et al. Antimicrobial action of a calcium binding leukocyte L-1 protein, calprotectin. Lancet 1990; 336: 763-5.
4. Isaksen B, Fagerhol MK. Calprotectin inhibits matrix metalloproteinases by sequestrion of zink. Mol Pathol 2001; 54: 289-92.
5. Yui S, Mikami M, Yamazaki M. Induction of apoptotic cell death in mouse lymphoma and human leukemia cell lines by a calcium-binding complex, calprotectin, derived from inflammatory peritoneal exudate cells. J Leukoc Biol 1995; 58: 650-8.
6. Berntzen HB, Olmez U, Fagerhol MK et al. The leukocyte protein L1 in plasma and synovial fluid from patients with rheumatoid arthritis and osteoarthritis. Scand J Rheumatol 1991; 20: 74-82.
7. Røseth AG, Fagerhol MK, Aadland E et al. Assessment of the neutrophil dominating protein calprotectin in feces. Scand J Gastroenterol 1992; 27: 793-8.
8. Bunn SK, Bisset WM, Main MJC et al. Faecal calprotectin: Validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001; 33: 14-22.
9. Fagerberg UL, Lööf L, Lindholm J et al. Fecal calprotectin: A quantitative marker of colonic inflammation in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007; 45: 414-20.
10. Costa F, Mumolo MG, Bellini M al. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis 2003; 35: 642-7.
11. Limburg PJ, Ahlquist DA, Sandborn WJ et al. Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy. Am J Gastroenterol 2000; 95: 2831-7.
12. Montalto M, Santoro L, Curgliano V et al. Faecal calprotectin concentrations in untreated celiac patients. Scand J Gastroenterol 2007; 42: 957-61.
13. Roseth A, Fagerhol MK, Wasiluk J et al. A new «calprotectin PoC device» correlates with ELISA and separates between endoscopic assessed mucosal healing and active ulcerative colitis. Gastroenterology Suppl 2007; 132: A175.
14. Drossman DA, Camilleri M, Mayer EA. AGA technical review on irritable bowel syndrome. Gastroenterology 2002; 123: 2108-31.
15. Suleiman S, Sonnenberg A. Cost-effectiveness of ndoscopy in irritable bowel syndrome. Arch Intern Med 2001; 161: 369-75.
16. Longstreth GF, Thompson WG, Chey WD et al. Functional bowel disorders. Gastroenterology 2006; 130: 1480-91.
17. Camilleri M, Williams DE. Economic burden of irritable bowel syndrome. Proposed strategies to control expenditures. Pharmacoeconomics 2000; 17: 331-8.
18. Tibble J, Teahon K, Thjodleifsson B et al. A simple method for assessing intestinal inflammation in Crohńs disease. Gut 2000; 47: 506-13.
19. Vermeeire S, van Assche G, Rutgeerts P. Laboratory markers in IBD; useful, magic, or unnecessary toys? Gut 2006; 55: 426-31.
20. Sipponen T, Savilathi E, Kolho KL et al. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: Correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis 2007; 13: 1-7.
21. D́Haens G, Sandborn WJ, Feagan BG et al. A review of activity indices and efficacy end points for clinical trial of medical therapy in adults with ulcerative colitis. Gastroenterology 2007; 132: 763-86.
22. Roseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein in patients with inflammatory bowel disease. Scand J Gastroenterol 1999; 34: 50-4.
23. Roseth AG, Aadland E, Jahnsen J et al. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 1997; 58: 176-80.
24. D́Haens G, Baert F, Vermeire S et al. Mucosal inflammation in inflammatory bowel disease can reliably be predicted with the fecal calprotectin test. Gastroenterology 2007; 132: A 174.
25. Tibble JA, Sigthorsson G, Bridger S et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000; 119: 15-22.
26. Bitton A, Peppercorn MA, Antonioli DA. Clinical, biological and histological parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2001; 120: 13-20.
27. Røseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol 2004; 39: 1017-20.
28. D́Haens G, Noman B, Rutgeerts P. Endoscopic healing after Infliximab treatment for Crohńs disease provides a longer time to relapse. Abstrakt. Gastroenterology 2002; 122: A100.
29. Frøslie KF, Jahnsen J, Moum BA et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007; 133: 412-22.
30. Rutgeerts P, Diamond RH, Bala M et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006; 63: 433-42.
31. Carroccio A, Iacono G, Cottone M et al. Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. Clin Chem 2003; 49: 861-7.
32. Fagerberg UL, Lööf L, Myrdal U et al. Colorectal inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms. J Pediatr Gastroenterol Nutr 2005; 40: 450-5.
33. von Roon AC, Karamountzos L, Purkayastha S et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol 2007; 102: 803-13.